PURPOSE: The purpose of the study was to clarify the incidence of B-raf oncogene (BRAF) mutations in primary cutaneous melanomas, their relation to tumor progression, and effect on disease outcome. Somatic mutations of BRAF kinase, a component of the Ras-mitogen-activated protein/extracellular signal-regulated kinase kinase-mitogen-activated protein kinase pathway, are frequently reported (>65%) in nevi and malignant melanomas. EXPERIMENTAL DESIGN: We assessed BRAF mutation frequency in exons 11 and 15 in primary (n = 59) and metastatic (n = 68) melanomas. Direct sequencing of PCR products was performed on DNA isolated and purified from microdissected tumors. RESULTS: Eighteen mutations (31%) at exon 15 were detected in primary melanoma with a significantly (P = 0.001) higher frequency in patients < 60 years old. Incidence of BRAF mutation did not correlate with Breslow thickness. Presence of BRAF mutation of primary tumors did not effect overall disease-free survival. BRAF mutation frequency in metastatic lesions was 57% and significantly (P = 0.0024) higher than primary melanomas. CONCLUSIONS: The study suggests that BRAF mutation may be acquired during development of metastasis but is not a significant factor for primary tumor development and disease outcome.
PURPOSE: The purpose of the study was to clarify the incidence of B-raf oncogene (BRAF) mutations in primary cutaneous melanomas, their relation to tumor progression, and effect on disease outcome. Somatic mutations of BRAF kinase, a component of the Ras-mitogen-activated protein/extracellular signal-regulated kinase kinase-mitogen-activated protein kinase pathway, are frequently reported (>65%) in nevi and malignant melanomas. EXPERIMENTAL DESIGN: We assessed BRAF mutation frequency in exons 11 and 15 in primary (n = 59) and metastatic (n = 68) melanomas. Direct sequencing of PCR products was performed on DNA isolated and purified from microdissected tumors. RESULTS: Eighteen mutations (31%) at exon 15 were detected in primary melanoma with a significantly (P = 0.001) higher frequency in patients < 60 years old. Incidence of BRAF mutation did not correlate with Breslow thickness. Presence of BRAF mutation of primary tumors did not effect overall disease-free survival. BRAF mutation frequency in metastatic lesions was 57% and significantly (P = 0.0024) higher than primary melanomas. CONCLUSIONS: The study suggests that BRAF mutation may be acquired during development of metastasis but is not a significant factor for primary tumor development and disease outcome.
Authors: Julie A Ellerhorst; Victoria R Greene; Suhendan Ekmekcioglu; Carla L Warneke; Marcella M Johnson; Carolyn P Cooke; Li-E Wang; Victor G Prieto; Jeffrey E Gershenwald; Qingyi Wei; Elizabeth A Grimm Journal: Clin Cancer Res Date: 2010-10-25 Impact factor: 12.531
Authors: Cathal P O'Brien; Stephen E Langabeer; Kenneth J O'Byrne; John J O'Leary; Stephen P Finn Journal: Mol Diagn Ther Date: 2014-02 Impact factor: 4.074
Authors: Carol Beadling; Michael C Heinrich; Andrea Warrick; Erin M Forbes; Dylan Nelson; Emily Justusson; Judith Levine; Tanaya L Neff; Janice Patterson; Ajia Presnell; Arin McKinley; Laura J Winter; Christie Dewey; Amy Harlow; Oscar Barney; Brian J Druker; Kathryn G Schuff; Christopher L Corless Journal: J Mol Diagn Date: 2011-07-02 Impact factor: 5.568
Authors: Minoru Kitago; Kazuo Koyanagi; Takeshi Nakamura; Yasufumi Goto; Mark Faries; Steven J O'Day; Donald L Morton; Soldano Ferrone; Dave S B Hoon Journal: Clin Chem Date: 2009-02-20 Impact factor: 8.327
Authors: N Narita; A Tanemura; R Murali; R A Scolyer; S Huang; T Arigami; S Yanagita; K K Chong; J F Thompson; D L Morton; D S Hoon Journal: Oncogene Date: 2009-06-29 Impact factor: 9.867